1-4 of 4
Gregory M. Hayes
Close
Sort by
Journal Articles

Kme-0584, a Highly Potent IRAK1/IRAK4/panFLT3 Inhibitor, Is a Promising Clinical Candidate for Hypomethylating Agent Plus Venetoclax Resistant AML/MDS Patients

Jan S. Rosenbaum, Amal S. Kolt, Scott B. Hoyt, Gregory M. Hayes, Brandi L. Soldo, Craig J. Thomas, Daniel T. Starczynowski
Journal: Blood
Blood (2023) 142 (Supplement 1): 4152.
https://doi.org/10.1182/blood-2023-189899
Published: 2023
Journal Articles

Kinetic Measurement of Leukemia-Cell Proliferation Rate By Deuterium Labeling Predicts Time to Initial Treatment of Patients with Chronic Lymphocytic Leukemia

Elizabeth J Murphy, MD DPhil, Donna Neuberg, ScD, Kanti R. Rai, MD, Laura Rassenti, PhD, Claire Emson, PhD, Kelvin Li, PhD, Neil E. Kay, MD, William G. Wierda, MD PhD, Gregory M Hayes, PhD, Jennifer R. Brown, MD PhD, John C. Byrd, MD, Coline McConnel, PhD, Jacqueline C. Barrientos, MD, Robert Allyn Redd, MS, Scott Turner, PhD, Robert Busch, PhD, Andrew Greaves, Marc Hellerstein, MD PhD, Nicholas Chiorazzi, MD, Thomas J. Kipps, MD PD
Journal: Blood
Blood (2014) 124 (21): 829.
https://doi.org/10.1182/blood.V124.21.829.829
Published: 2014
Journal Articles

IGN523: A Therapeutic Anti-CD98 Antibody With Multiple Mechanisms Of Action Demonstrates Anti-Tumor Efficacy

Gregory M. Hayes, Lawrence Chinn, Joseph M. Cantor, Timothy Velilla, Mark H. Ginsberg, Edward H. van der Horst
Journal: Blood
Blood (2013) 122 (21): 1462.
https://doi.org/10.1182/blood.V122.21.1462.1462
Published: 2013
Journal Articles

Expression of CD38 and High Levels of CD5 Identifies Members of CLL Clones That Have Progressed beyond G1 and Proliferated.

Carlo Calissano, MD, Rajendra N. Damle, PhD, Marc Hellerstein, MD, Elisabeth J. Murphy, MD, Gregory M. Hayes, PhD, Kaufman Matthew, MD, Steven Allen, MD, Kanti Rai, MD, Nicholas Chiorazzi, MD
Journal: Blood
Blood (2007) 110 (11): 1114.
https://doi.org/10.1182/blood.V110.11.1114.1114
Published: 2007